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AntioxidantAbstract Aconvenient one-pot, three-component synthesis of 2, 6-bis (1-coumarin-2-yl)-4-(4-substi-
tuted phenyl) pyridine derivatives (3a–k) by Chichibabin reaction has been reported. These com-
pounds were synthesized by the reaction of 3-acetyl coumarin (1a) or 5-bromo 3-acetyl coumarin
(1b) with substituted aromatic aldehydes (2a–k) and ammonium acetate under acidic conditions
and the structure was conﬁrmed by FT-IR, 1H NMR, 13C NMR and Mass spectroscopic methods.
The newly synthesized compounds (3a–k) were evaluated for antimicrobial activity, DPPH free radical
scavenging activity and ferrous ion-chelating ability. Themode of action of these active compoundswas
carried out by docking receptorGlcN6P synthase. Compounds 3a, 3b, 3c, and 3d have displayed poten-
tial antimicrobial activity and some of the compounds have shown promising antioxidant properties.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Coumarin derivatives containing pyridine heterocycle
(Brahmbhatt and Pandya, 2001, 2003; Brahmbhatt et al.,
2004, 2005, Brahmbhatt et al., 2007; Niraj et al., 2010) are
known to exhibit anticoagulant, antibacterial and antifungal
activities (Brahmbhatt et al., 2010). Pyridine scaffolds have been
found in numerous naturally occurring compounds and are also
frequently used in functional materials (Muller and Bunz, 2007;
McKillop and Boulton, 1984; Jones, 1996; Spitzner, 2004).
Synthesis of some 2, 6-bis (1-coumarin-2-yl)-4-(4-substituted phenyl) pyridine derivatives as potent biological agents S1337Pyridine-diol derivatives are of particular interest as building
blocks for the construction of dendritic nanostructures in supra-
molecular chemistry (Christinat et al., 2007), whereas N-pro-
tected pyridine-3, 4-diols ﬁnd applications as potent chelating
agents in medicinal chemistry (Dehkordi et al., 2008). Further-
more, perﬂuorinated heteroaromatic compounds are interesting
synthetic intermediates for the development of novel pharma-
ceuticals (Negwer, 1994). Coumarin nucleus has been the aim
of many researchers as most of its derivatives were proved to
be bioactive as antibacterial, antifungal, antioxidant (Murray
et al., 1982; Nermien et al., 2011;Hamdi et al., 2008; Kenchappa
et al., 2013) anticoagulant (Miky and Farrag, 1997), anticancer
(Via et al., 1999; Bhattacharyya et al., 2009), anthelmentic (Lee
et al., 1998) and antitumor (Tegginamath et al., 2011). Much re-
search has been focused on the inhibition of bacterial growth by
naturally occurring coumarins (xanthoxin, herniarin, umbellif-
erone, and scopoletin) and on the antifungal activity of umbel-
liferone, scopoletin, and coumarin itself (Hamdi et al., 2008).
In modern drug designing, molecular docking is routinely
used for understanding drug-receptor interaction. This method
has been frequently used to predict the binding afﬁnity and ori-
entation of small drugmolecules at the active site of their protein
targets (Vijesh et al., 2013).When designing novel antimicrobial
agents, enzymes involved in the biosynthesis of microbial cell
walls are generally good targets. In this regard, glucosamine-
6-phosphate synthase, which is liable for the synthesis of D-glu-
cosamine-6-phosphate, is particularly attractive because it is
involved in the ﬁrst step for the formation of the core amino-
sugar, N-acetyl glucosamine that is an essential part of the
unique peptidoglycan and chitin components of the cell walls
of bacteria and fungi, respectively (Marshall et al., 2003).
The concept of divergence and convergence in organic syn-
thesis is very useful. Convergent synthesis pathways generally
show advantages over linear or divergent approaches with re-
spect to speed, time, yield, and reproducibility. Among organic
reactions, multicomponent reactions are highly convergent
(Beck et al., 2000). During a multicomponent reaction, more
than two starting materials are assembled to afford a complex
product. Up to seven-component reactions have been de-
scribed so far (Domling and Ugi, 1993). Therefore, they
constitute a superior tool for diversity-oriented and complex-
ity-generating synthesis for drug discovery (Lee et al., 2000).
In view of the above facts, in the present work we have devel-
oped a simple and convenientmethod for the synthesis of 2, 6-bis
(1-coumarin-2-yl)-4-(4-substituted-phenyl) pyridine derivatives
and evaluated for antimicrobial and antioxidant activities.
2. Materials and methods
2.1. Chemistry
Melting points were recorded on electro thermal melting point
apparatus and are uncorrected. 1H and 13C NMR spectra were
recorded on Bruker 400 MHz spectrometer and chemical shifts
are shown in d values (ppm) with tetramethylsilane (TMS) as
internal standard. LC–MS were obtained using Agilent LC/
MS instrument. The FT-IR spectra were taken in KBr pellets
(100 mg) using Shimadzu FT-IR spectrophotometer. Column
chromatography was performed using silica gel (230–400
mesh), silica gel GF254 plates from Merck were used for
TLC and spots were identiﬁed either by UV or dipping the
plates in potassium permanganate solution.General procedure for the synthesis of 2, 6-bis (1-coumarin-
2-yl)-4-(4-substituted phenyl) pyridine derivatives (3a–k).
Two equivalents of 3-acetyl coumarin (1a) or 5-bromo 3-
acetyl coumarin (1b), one equivalent of aromatic aldehydes
(2a–k) and 1.5 equivalent of ammonium acetate were dissolved
in acetic acid and the reaction mixture was reﬂuxed for about
8–10 h in an oil bath at the temperature of 110–115 C. After
completion of the reaction, the reaction mixture was kept at
room temperature overnight, and poured into ice cold water.
The solid separated was ﬁltered and washed with sodium
bicarbonate solution and recrystallized using ethanol.
2.1.1. 3-(6-(2-Oxo-2H-chromen-3-yl)-4-phenylpyridin-2-yl)-
2H-chromen-2-one (3a)
Yield 79%; m.p; 251–253 C, (lit. m.p; 253–254 C); white so-
lid (Anil et al., 2010).
2.1.2. 3-(4-(4-Chlorophenyl)-6-(2-oxo-2H-chromen-3-yl)
pyridin-2-yl)-2H-chromen-2-one (3b)
Yield 90%; m.p; 162–165 C; white solid; mol. formula;
C29H16ClNO4; IR (KBr): 3063 (Ar–H), 1718 (coumarin
C‚O), 1613 (C‚N), 1559, 749, 693 cm1; 1H NMR (CDCl3,
400 MHz) d: 7.33–7.81 (12H, m, Ar–H), 8.64 (2H, s, 3-H and
5-H of pyridine ring), 8.87 (2H, s, 40-H and 400-H of coumarin
rings); 13C NMR: d 116.4, 119.5, 121.8, 124.6, 125.3, 127.4,
128.9, 129.1, 129.2, 132.3, 138.0, 142.8, 149.8, 151.4, 154.0,
160.3; MS: m/z 477.89 [M+], 479.50 [M + 2].
2.1.3. 6-Bromo-3-(6-(6-bromo-2-oxo-2H-chromen-3-yl)-4-
phenylpyridin-2-yl)-2H-chromen-2-one (3c)
Yield 86%; m.p; 158–162 C; light yellow solid; mol. formula;
C29H15Br2NO4; IR (KBr): 3055, 1723, 1606, 1531, 823 cm
1;
1H NMR(CDCl3, 400 MHz) d: 7.38–7.95 (11H, m, Ar–H),
8.65 (2H, s, 3-H and 5-H of pyridine ring), 8.88 (2H, s, 40-H
and 400-H of coumarin rings); 13C NMR: d 116.4, 119.5,
121.5, 124.6, 125.4, 127.2, 128.9, 129.8, 132.3, 135.1, 139.4,
142.8, 149.8, 151.4, 154.0, 160.3; MS: m/z= 601.24 [M+],
603.25 [M + 2], 605.24 [M + 4].
2.1.4. 6-Bromo-3-(6-(6-bromo-2-oxo-2H-chromen-3-yl)-4-(4-
chlorophenyl) pyridin-2-yl)-2H-chromen-2-one (3d)
Yield 83%; m.p; 160–164 C; light yellow solid; mol. formula;
C29H14Br2ClNO4; IR (KBr): 3055, 1720, 1608, 1535, 825 cm
1;
1H NMR(CDCl3, 400 MHz) d: 7.37–7.96 (10H, m, Ar–H),
8.64 (2H, s, 3-H and 5-H of pyridine ring), 8.82 (2H, s, 40-H
and 400-H of coumarin rings); 13C NMR: d 116.4, 119.5,
121.5, 124.6, 125.4, 127.2, 128.9, 129.8, 132.3, 135.1, 139.4,
142.8, 149.8, 151.4, 154.0, 160.3; MS: m/z= 635.68 [M+],
637.68 [M + 2], 639.68 [M + 4].
2.1.5. 3-(6-(2-oxo-2H-chromen-3-yl)-4-p-tolylpyridin-2-yl)-
2H-chromen-2-one (3e)
Yield 85%; m.p; 266–268 C; (lit. m.p; 269–270 C); white so-
lid (Anil et al., 2010).
2.1.6. 3-(4-(4-(Dimethylamino) phenyl)-6-(2-oxo-2H-
chromen-3-yl) pyridin-2-yl)-2H-chromen-2-one (3f)
Yield 76%; m.p; 161–164 C, light yellow solid; mol. formula;
C31H22N2O4; IR (KBr): 3055, 1720, 1608, 1535, 825 cm
1; 1H
NMR (CDCl3, 400 MHz) d: 2.97 (6H, s, N(CH3)2), 7.34–7.91
S1338 R. Kenchappa et al.(12H, m, Ar–H), 8.59 (2H, s, 3-H and 5-H of pyridine ring), 8.78
(2H, s, 40-H and 400-H of coumarin rings); 13C NMR: d 20.4,
115.4, 121.5, 123.3, 124.0, 125.1, 126.6, 128.9, 131.4, 134.1, 136.5,
140.5, 143.9, 149.8, 151.4, 152.0, 160.2; MS: m/z 486.51 [M+].
2.1.7. 3-(4-(2-Fluorophenyl)-6-(2-oxo-2H-chromen-3-yl)
pyridin-2-yl)-2H-chromen-2-one (3g)
Yield 91%; m.p; 75–80 C, light yellow solid; Mol. Formula;
C29H16FNO4; IR (KBr): 3048, 1723, 1605, 1538, 821 cm
1;
1H NMR (CDCl3, 400 MHz) d: 7.39–7.96 (12H, m, Ar–H),
8.55 (2H, s, 3-H and 5-H of pyridine ring), 8.71 (2H, s, 40-H
and 400-H of coumarin rings); 13C NMR: d 116.4, 120.5,
122.3, 123.5, 125.6, 126.1, 127.9, 131.8, 133.1, 136.5, 142.5,
143.9, 150.8, 151.6, 152.6, 162.2; MS: m/z 461.44 [M+].
2.1.8. 3-(4-(3-Fluorophenyl)-6-(2-oxo-2H-chromen-3-yl)
pyridin-2-yl)-2H-chromen-2-one (3h)
Yield 75%; m.p; 155–158 C, light yellow solid; Mol. Formula;
C29H16FNO4; IR (KBr): 3035, 1719, 1610, 1540, 826 cm
1; 1H
NMR (CDCl3, 400 MHz) d: 7.28–7.85 (12H, m, Ar–H), 8.57
(2H, s, 3-H and 5-H of pyridine ring), 8.75 (2H, s, 40-H and
400-H of coumarin rings); 13C NMR: d 115.4, 121.0, 122.1,
123.6, 125.8 (C), 126.6, 128.7, 132.6, 133.1, 137.3, 141.9,
143.6, 150.2 (C), 151.6, 152.6, 161.0; MS: m/z 461.44 [M+].
2.1.9. 1.9. 3-(4-(4-Fluorophenyl)-6-(2-oxo-2H-chromen-3-yl)
pyridin-2-yl)-2H-chromen-2-one (3i)
Yield 84%; m.p; 95–98 C, light yellow solid; mol. formula;
C29H16FNO4; IR (KBr): 3031, 1710, 1625, 1543, 821 cm
1;
1H NMR (CDCl3, 400 MHz) d: 7.21–7.78 (12H, m, Ar–H),
8.56 (2H, s, 3-H and 5-H of pyridine ring), 8.70 (2H, s, 4’-H
and 400-H of coumarin rings); 13C NMR: d 114.4, 120.3,
121.1, 123.6, 124.2, 125.4, 127.3, 131.5, 133.1, 136.7, 140.6,
142.4, 150.2, 151.6, 153.6, 161.0 (C); MS: m/z 461.44 [M+].
2.1.10. 3-(4-(4-Nitrophenyl)-6-(2-oxo-2H-chromen-3-yl)
pyridin-2-yl)-2H-chromen-2-one (3j)
Yield 81%; m.p; 97–99 C, light yellow solid; mol. formula;
C29H16N2O6; IR (KBr): 3069, 1718, 1625, 1525, 820 cm
1;
1H NMR (CDCl3, 400 MHz) d: 7.03–7.81 (12H, m, Ar–H),
8.65 (2H, s, 3-H and 5-H of pyridine ring), 8.86 (2H, s, 40-H
and 400-H of coumarin rings); 13C NMR: d 52.5, 113.0, 115.5,
116.6, 120.4, 121.1, 123.2, 125.4, 127.6, 128.4, 130.2, 133.2,
145.8, 151.3,153.0, 161.3, 160.7; MS: m/z 488.44 [M+].
2.1.11. 3-(4-(4-Methoxyphenyl)-6-(2-oxo-2H-chromen-3-yl)
pyridin-2-yl)-2H-chromen-2-one (3k)
Yield 87%; m.p; 275–277 C; light yellow solid; mol. formula;
C30H19NO5; IR (KBr): 3065, 1710, 1615, 1520, 823 cm
1; 1H
NMR (CDCl3, 400 MHz) d: 3.90 (3H, s, OCH3), 7.02–7.80 (12H,
m, Ar–H), 8.62 (2H, s, 3-H and 5-H of pyridine ring), 8.88 (2H, s,
40-H and 400-H of coumarin rings); 13C NMR: d 55.5, 113.9, 114.5,
116.4, 119.5, 121.1, 124.6, 125.4, 128.6, 128.9, 130.2, 132.2,
142.8, 151.3, 154.0, 160.3, 160.7; MS: m/z 473.47 [M+].
2.2. Pharmacology
2.2.1. Antimicrobial activity
The newly synthesized compounds were screened for antibac-
terial activity against one gram-positive bacterium, Bacillussubtilis and three Gram-negative bacteria Pseudomonas aeru-
ginosa, E. coli and Salmonella typhi. Antifungal activity was
screened against four fungal strains, Aspergillus ﬂavus, Can-
dida albicans, Microspora griseous, and Aspergillus terreus.
Dimethylsulfoxide was used as solvent control. The bacterial
culture was inoculated on nutrient agar (Merck) and fungal
culture was inoculated on potato dextrose agar media
(20 mL) and poured into sterilized Petri dishes (99 mm). Media
plates were inoculated with liquid cultures homogeneously by
spread plate method.
All the test compounds were dissolved in dimethylsulfoxide
(DMSO) to get a concentration of 100 lL and loaded into the
wells of agar plates directly. Plates inoculated with the bacteria
were incubated at 37 C for 24 h and the fungal culture was
incubated at 25 C for 72 h. All determinations were done in
triplicates. Amoxicillin and Gentamicin (1.64, 0.64, and
0.25 mg/mL) were used as standard drugs for antibacterial
and antifungal activities respectively.
2.2.2. In silico molecular docking studies
The newly synthesized compounds were subjected to molecular
docking studies using Auto Dock (version 4.2) with
Lamarckian genetic algorithm (Roseman, 2001; Milewski,
2002; Milewski et al., 2006; Whelan and Ballou, 1975).The syn-
thesized ligand molecules having 2D structure were converted
into energy minimized 3D structures and were further used for
in silico protein–ligand docking. The docking of receptor
GlcN-6-P with newly synthesized ligands exhibited well
established bonds with one or more amino acids in the receptor
active pocket. The active pocket was considered to be the site
where glucosamine-6-phosphate complexes with GlcN-6-P of
2VF5. The active pocket consisted of 12 amino acid residues
as Ala602, Val399, Ala400, Gly301, Thr302, Ser303, Cys300,
Gln348, Ser349, Thr352, Ser347, and Lys603 (Wallace et al.,
1995).
The crystal structure of GlcN-6-P synthase (PDB ID 2VF5)
from the PDB (http://www.pdb.org/pdb/home/home.do) was
selected and edited by removing the heteroatoms and adding
C-terminal oxygen (Binkowski et al., 2003). The graphical user
interface program ‘‘Auto Dock Tools’’ was used to prepare,
run and analyze the docking simulations. Kollman united
atom charges, solvation parameters and polar hydrogens were
added to the receptor for the preparation of protein in docking
simulation. Since ligands are not peptides, Gasteiger charge
was assigned and then non-polar hydrogens were merged.2.2.3. Antioxidant activity
2.2.3.1. Scavenging effect on stable radical 1, 1-diphenyl-
picrylhydrazyl (DPPH). Free radical-scavenging capacities of
different compounds were determined according to the re-
ported procedure (Braca et al., 2001). Freshly prepared DPPH
solution was taken in test tubes and newly synthesized com-
pounds were added (100 lg) to each test tube so that the ﬁnal
volume will be 3 mL. After 10 min, the absorbance was re-
corded at 517 nm using a UV–Visible spectrophotometer
(Shimadzu UV-1800, Japan). Butylatedhydroxytoluene
(BHT) dissolved in distilled water was used as a reference.
Control sample was prepared using the same volume without
any compound and reference BHT, 95% methanol served as
blank. The variation exhibited in DPPH scavenging capacity
could be attributed to the effect of different substitutions. Test
Synthesis of some 2, 6-bis (1-coumarin-2-yl)-4-(4-substituted phenyl) pyridine derivatives as potent biological agents S1339was performed in triplicate and the results were averaged.
Radical scavenging activity was calculated using the formula.
% of Radical scavenging activity
¼ ½ðAcontrol  AtestÞ=Acontrol  100
where Acontrol is the absorbance of the control sample and Atest
is the absorbance of the test sample.
2.2.3.2. Chelating effects on ferrous ions. The chelating effect
was determined according to the method of Decker and welch
(1990), (Nevcihan et al., 2010). In brief, 2 mL of different con-
centrations (0.5–2.0 mg/mL) of the compound in methanol
was added to a solution of 2 mM FeCl2 (0.05 mL). The reac-Table 1 Zone of inhibition of synthesized compounds (3a–k).
Comp no. Conc mg/mL Zone of inhibition in mm (mean ± S.D.) n
Antibacterial
P.a± S.D B.s± S.D* S.t± S.D* E
3a 1.6 20 ± 0.20 34 ± 0.10 35 ± 0.30
0.64 30 ± 0.20 32 ± 0.20 33 ± 0.20
0.25 32 ± 0.20 28 ± 0.30 32 ± 0.10
3b 1.6 18 ± 0.10 24 ± 0.10 21 ± 0.20 2
0.64 14 ± 0.20 14 ± 0.20 17 ± 0.10 1
0.25 13 ± 0.10 13 ± 0.10 14 ± 0.10 1
3c 1.6 20 ± 0.10 36 ± 0.30 35 ± 0.30 1
0.64 15 ± 0.20 32 ± 0.20 35 ± 0.10 1
0.25 14 ± 0.20 27 ± 0.10 22 ± 0.20 1
3d 1.6 18 ± 0.20 36 ± 0.20 34 ± 0.30 1
0.64 14 ± 0.10 34 ± 0.30 34 ± 0.10 1
0.25 13 ± 0.20 29 ± 0.20 20 ± 0.20
3e 1.6 18 ± 0.30 17 ± 0.10 16 ± 0.10 1
0.64 14 ± 0.10 15 ± 0.20 16 ± 0.10 1
0.25 09 ± 0.20 10 ± 0.10 10 ± 0.20 1
3f 1.6 – – –
0.64 13 ± 0.20 12 ± 0.30 18 ± 0.10 1
0.25 08 ± 0.10 10 ± 0.10 12 ± 0.20 1
3g 1.6 19 ± 0.30 18 ± 0.30 17 ± 0.30 1
0.64 17 ± 0.10 18 ± 0.20 14 ± 0.20 1
0.25 12 ± 0.20 10 ± 0.10 09 ± 0.10 1
3h 1.6 20 ± 0.30 20 ± 0.30 – 1
0.64 17 ± 0.10 18 ± 0.10 12 ± 0.20 1
0.25 10 ± 0.10 12 ± 0.20 0.8 ± 0.10 1
3i 1.6 18 ± 0.30 20 ± 0.30 17 ± 0.10 2
0.64 16 ± 0.20 19 ± 0.10 17 ± 0.20 1
0.25 10 ± 0.10 08 ± 0.20 09 ± 0.30 1
3j 1.6 20 ± 0.30 18 ± 0.10 21 ± 0.20 1
0.64 18 ± 0.10 16 ± 0.10 20 ± 0.30 1
0.25 12 ± 0.20 10 ± 0.30 13 ± 0.20 1
3k 1.6 18 ± 0.30 17 ± 0.20 21 ± 0.10 1
0.64 16 ± 0.20 16 ± 0.10 19 ± 0.20 1
0.25 13 ± 0.10 10 ± 0.20 12 ± 0.10 1
Standa 1.6 26 ± 0.30 36 ± 0.30 36 ± 0.20 2
0.64 22 ± 0.20 28 ± 0.10 30 ± 0.40 2
0.25 19 ± 0.10 20 ± 0.20 23 ± 0.10 1
Standb – – – –
– – – –
– – – –
P.a, Pseudomonas aeruginosa; B.s, Bacillus subtilis; S.t, Salmonella typhi; E
Microspora griseous; A.t, Aspergillus terreus.
a Stand – Amoxicillin.
b Stand – Gentamicin.
* S.D – Standard deviation.tion was initiated by the addition of 5 mM ferrozine
(0.2 mL) and total volume was adjusted to 5 mL with metha-
nol. Then, the mixture was shaken vigorously and left at room
temperature for 10 min. Absorbance of the solution was mea-
sured spectrophotometrically at 562 nm.
The inhibition percentage of ferrozine-Fe+2 complex for-
mations was calculated using the formula given below.
Metal chelating effect ð%Þ ¼ ½ðAcontrol  AsampleÞ=Acontrol  100
where Acontrol is the absorbance of control (the control
contains FeCl2 ferrozine complex formation molecules) and
Asample is the absorbance of the test compound. Ascorbic acid
is used as control.= 3
Antifungal
.c± S.D* A.f± S.D* C.a± S.D* M.g± S.D* A.t± S.D*
– 22 ± 0.20 19 ± 0.30 30 ± 0.50 20 ± 0.20
– 21 ± 0.50 18 ± 0.40 19 ± 0.20 12 ± 0.10
– 17 ± 0.10 15 ± 0.20 16 ± 0.10 11 ± 0.20
2 ± 0.40 20 ± 0.20 14 ± 0.10 22 ± 0.20 17 ± 0.50
6 ± 0.10 12 ± 0.30 13 ± 0.20 18 ± 0.10 12 ± 0.20
0 ± 0.20 08 ± 0.20 09 ± 0.20 10 ± 0.20 07 ± 0.20
6 ± 0.10 21 ± 0.50 16 ± 0.50 34 ± 0.10 19 ± 0.20
3 ± 0.30 19 ± 0.20 18 ± 0.20 21 ± 0.30 12 ± 0.20
0 ± 0.10 13 ± 0.20 11 ± 0.20 15 ± 0.40 09 ± 0.20
7 ± 0.50 21 ± 0.10 21 ± 0.10 19 ± 0.20 20 ± 0.20
4 ± 0.30 17 ± 0.20 20 ± 0.30 15 ± 0.10 12 ± 0.30
– 14 ± 0.30 15 ± 0.20 12 ± 0.20 10 ± 0.20
7 ± 0.40 09 ± 0.20 03 ± 0.20 – 10 ± 0.10
5 ± 0.30 05 ± 0.10 01 ± 0.30 – 01 ± 0.20
2 ± 0.10 – – – –
– 13 ± 0.20 01 ± 0.20 12 ± 0.30 01 ± 0.30
8 ± 0.50 – – – –
0 ± 0.30 – – – –
8 ± 0.10 15 ± 0.10 03 ± 0.10 – 01 ± 0.20
8 ± 0.40 13 ± 0.20 02 ± 0.20 – 01 ± 0.10
2 ± 0.20 10 ± 0.30 02 ± 0.10 – –
8 ± 0.10 12 ± 0.50 03 ± 0.20 – 03 ± 0.10
7 ± 0.30 12 ± 0.20 03 ± 0.20 – 01 ± 0.10
.0 ± 0.50 04 ± 0.10 – – –
0 ± 0.20 07 ± 0.20 – – 12 ± 0.10
2 ± 0.40 05 ± 0.30 – – 10 ± 0.20
0 ± 0.10 – – – 06 ± 0.10
9 ± 0.20 10 ± 0.20 – – 13 ± 0.20
6 ± 0.50 10 ± 0.10 – – 10 ± 0.30
0 ± 0.30 07 ± 0.40 – – 05 ± 0.20
7 ± 0.20 02 ± 0.30 – – 03 ± 0.10
5 ± 0.10 01 ± 0.20 – – 10 ± 0.10
0 ± 0.10 – – – –
4 ± 0.20 – – – –
0 ± 0.30 – – – –
6 ± 0.20 – – – –
– 24 ± 0.20 20 ± 0.10 34 ± 0.30 22 ± 0.30
– 20 ± 0.50 16 ± 0.20 28 ± 0.20 20 ± 0.10
– 20 ± 0.10 18 ± 0.30 20 ± 0.40 20 ± 0.20
.c, Escherichia coli; A.f, Aspergillus ﬂavus; C.a, Candida albicans;M.g,
Table 2 Minimum inhibitory concentration (lg/ml) of compounds (3a–k).
Comp. no. Minimum inhibitory concentration (MIC lg/mL)
P.a B.s S.t E.c A.f C.a M.g A.t
3a 16.02 15.90 16.09 – 12.60 12.65 12.65 13.95
3b 20.32 23.56 18.26 19.45 12.60 15.51 17.55 22.54
3c 15.80 15.90 16.91 15.94 21.50 25.50 21.50 18.57
3d 15.88 15.90 16.91 15.96 52.32 65.36 75.12 63.12
3e 30.21 35.56 36.65 28.85 NT NT NT NT
3f NT NT NT NT NT NT NT NT
3g 100.65 95.26 96.95 95.26 95.34 68.24 56.15 39.45
3h 102.32 82.36 98.59 102.76 22.5 59.64 72.19 56.14
3i 49.36 59.46 76.36 65.36 NT NT NT NT
3j 30.25 28.85 35.46 33.19 NT NT NT NT
3k 120.32 110.36 104.26 96.37 NT NT NT NT
Amoxicillin 15.50 15.50 15.50 15.50 – – – –
Gentamicin – – – – 12.50 12.50 12.50 12.50
NT – not tested.
P.a, Pseudomonas aeruginosa; B.s, Bacillus subtilis; S.t, Salmonella typhi, E.c, Escherichia coli; A.f, Aspergillus ﬂavus; C.a, Candida albicans;M.g,
Microspora griseous; A.t, Aspergillus terreus.
Figure 1 Interaction of ligand molecules 3a, 3b, 3c, 3d, Amo, Gent, with GlcN-6-P, Amo, Gent, represents interaction of amoxicilin and
gentamicin (standards) with GlcN-6-P respectively. (In all the images the ligands are represented in green color and the target protein
GlcN-6-P in Secondary structure and secondary colorization).
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Synthesis of some 2, 6-bis (1-coumarin-2-yl)-4-(4-substituted phenyl) pyridine derivatives as potent biological agents S13413. Results and discussion
3.1. Chemistry
We report herein, a simple and expeditious synthesis of highly
substituted pyridines in excellent yield. The starting com-
pounds (1a–b) were synthesized according to the literature
method (Vijesh et al., 2010). In a typical procedure a 2:1:1.5
mixture of 3-acetyl coumarin (1a) or 5-bromo 3-acetyl couma-
rin (1b), substituted aromatic aldehydes (2a–k) and ammo-
nium acetate were reﬂuxed in acetic acid at 110 C to furnish
the Chichibabin products (3a–k) in good yields. The method
involves the formation of imine by the reaction of 3-acetyl cou-
marin with ammonia. In the second step aldol condensation
takes place between substituted aldehyde and enolate ion of
3 acetyl coumarin and in the ﬁnal step Michael addition reac-
tion takes place between coumarin chalcone and imines. From
a mechanistic standpoint (Farley and Eliel, 1956; Frank and
Seven, 1949; Frank and Riener1950), ammonia serves two
functions and occurs through the formation of enamine with
a third equivalent of aldehyde. The Michael addition of enam-
ine to enolate followed by cyclization gives rise to a ﬁnal com-
pound (see Scheme 1).
IR Spectroscopic analysis of the newly synthesized com-
pounds (3a–k) revealed that the strong absorption band at
3053–3073 cm1 corresponds to the Ar–H stretching vibration.
The sharp absorption bands at 660–662 and 740–748 cm1
correspond to the presence of C–Br, C–Cl group on the phenyl
ring. Compound 3j exhibited the strong absorption band at
1625 and 1525 cm1 which correspond to symmetric and
asymmetric frequency of the NO2 group on the phenyl ring.
The chemical shift (1H NMR) observed in the range of d
7.03 and 7.96 corresponds to the aromatic protons, the singlet
in the range of 8.55 and 8.66 ppm corresponds to two protons
of the pyridine ring and another singlet at 8.70–8.89 ppm cor-
responds to two protons (40-H and 400-H) of the coumarin ring.
The structure was further conﬁrmed by 13C NMR which was
in agreement with the synthesized compounds. The mass spec-
tra of these compounds displayed a molecular ion peak at
appropriate m/z values corresponding to the respective molec-
ular formulae.
3.2. Pharmacology
3.2.1. In vitro antibacterial and antifungal activities
The newly synthesized compounds (3a–k) were evaluated for
their antimicrobial activity using agar-well diffusion method
at three different concentrations and the results are given in
Table 1. The investigation of antimicrobial screening revealed
that, test compounds showed varying degrees of activity
against all the tested microorganisms. The activity of these
compounds was found to be concentration dependent.
Further, the compounds which showed a good zone of inhi-
bition were studied for minimum inhibitory concentration
(MIC) using serial broth-dilution method to quantify the anti-
microbial potency of the compounds. MIC was performed at
different concentrations i.e. 1, 10, 25, 50,100, and 150 lg/mL
and the results have been given in Table 2. It is clear from
our present ﬁndings that heterocyclic systems with electron
withdrawing and donating groups on the phenyl ring and theT C 3 3 3 3 A G
S1342 R. Kenchappa et al.coumarin moiety play an important role in varying the efﬁcacy
of antimicrobial activity.
The role of electron withdrawing group in improving anti-
microbial activities had been reported in the literature (Sharma
et al., 2004).
The investigation of MIC of the tested compounds revealed
that the compound 3a with no substitution on phenyl ring,
compounds 3c and 3d substituted with electron withdrawing
groups have shown MIC’s at lowest concentration ranging
from 15.80–16.91 lg/mL against tested bacterial organisms
as compared with the standard Amoxicillin. Compound 3c
showed MIC value of 21.50 lg/mL against tested fungal
organisms A. ﬂavus, M. griseous; compound 3a is inactive
against E. coli, compounds 3a and 3b (Cl-group on phenyl
ring) have shown a MIC value of 12.60 lg/mL against A. ﬂavus
and compound 3b have shown good inhibition with a MIC va-
lue of 12.65 and 12.68 lg/mL against C. albicans and
M. griseous respectively, when compared with the standard
Gentamicin. Compound 3b exhibited moderate to good inhibi-
tion with a MIC value of 18.26 and 15.51 lg/mL against S. ty-
phi and C. albicans respectively. Compound 3h have shown a
MIC value of 22.50 lg/mL against A. ﬂavus. Remaining tested
compounds showed varying degrees of MIC values ranging
from 30.21 to 120.32 lg/mL.
To compare the binding afﬁnity of the newly synthesized
compounds, they were subjected for molecular docking using
Auto Dock (version 4.2) with Lamarckian genetic algorithm.
The newly synthesized compounds 3a, 3b, 3c, and 3d were ana-
lyzed for their mechanism of antimicrobial action.
The estimated binding energy between the protein and li-
gand for each molecule was compared to substantiate the
experimental results. The compounds which have exhibited
the bonding with one or the other amino acids in the active
pockets are shown in Fig. 1.
The docking of GlcN-6-P synthase with 3a, 3b, 3c, and 3d
revealed that the image 3d with least binding energy
(6.05 kJ mol1) and which also establishes two hydrogen
bonds between coumarin lactone with gln 348, and another
coumarin lactone with lys 603 amino acids in the active site
of the target protein with minimum bond length (1.848 and
1.874 A˚) has the highest afﬁnity and hence is the best dock
conformation Binding energy inhibition constant, RMS value,
ligand efﬁciency, number of hydrogen bonds, and bond length
of four tested compounds and two standards were recorded in
each ligand conﬁrmations and are given in Table 3.
By comparing antimicrobial activity and docking results,
we concluded that heterocyclic derivatives containing oxygen
in the coumarin seem to be potentially active drugs.Table 4 Scavenging effect of synthesized compounds (3a–k)
on stable radical 1, 1-diphenyl-picrylhydrazyl (DPPH).
Comp. no. DPPH assay in % Comp. no. DPPH assay in %
3a 26.3 ± 0.23 3g 35.3 ± 0.28
3b 68.6 ± 0.61 3h 78.3 ± 0.16
3c 52.5 ± 0.45 3i 56.2 ± 0.35
3d 74.1 ± 0.14 3j 27.3 ± 0.12
3e 38.7 ± 0.35 3k 28.7 ± 0.11
3f 37.2 ± 0.26 BHT 90.42 ± 0.25
Each value is expressed as mean ± SD of three replicates.
Butylatedhydroxytoluene (BHT) used as standard.3.3. Scavenging effect on stable radical 1, 1-diphenyl-
picrylhydrazyl (DPPH)
The newly synthesized compounds (3a–k) were tested for 2, 2-
diphenyl-1-picryhydrazyl (DPPH) radical scavenging activity
with butylatedhydroxytoluene (BHT) as standard and the re-
sults are tabulated in Table 4. It has been reported that the het-
erocyclic systems with halogen substituent have shown better
antioxidant properties than other substituent (Hossain et al.,
2009; Ferreira et al., 2006).
The investigation of (DPPH) radical scavenging activity re-
vealed that compounds with electron withdrawing substituents
such as Br and Cl (3b, 3d, and 3h) displayed very good anti-
oxidant activity. The other tested compounds showed moder-
ate to good antioxidant activity.
3.4. Chelating ability of metal ion
It has been well known that transition metal ions such as those
of iron and copper are important catalysts for the generation
of free radicals to initiate the radical chain reaction or the rad-
ical mediates lipid peroxidation (Nawar, 1996).It has been re-
ported that the compounds containing two or more of the
following functional groups: OH, COOH, C‚O, NR2 and O
in a favorable structure–function conﬁguration can show the
activity of metal chelation (Yuan et al., 2005).The ferrous
ion-chelating activities of the newly synthesized compounds
are shown in Fig. 2.The range and mean of Fe+2 chelating
capacities varied signiﬁcantly among different compounds on
the basis of substitution on the phenyl ring.
Due to extra stabilization, compounds 3d and 3h would
have higher aptitude to trap radical in a faster rate than the
other similar type of molecules. Compounds 3a, 3c, and 3g
showed very good chelating ability, whereas compounds 3i
and 3j have shown comparable activity with the standard
EDTA. The compounds substituted with electron donating
groups (3f, 3e, and 3k) showed signiﬁcantly lesser activity.
The metal-chelating effect of the tested compounds with re-
spect to electron withdrawing substituent on the phenyl ring
is in the order of EDTA> 2-F > 4-F > 4-NO2 > 4-Cl > 3-
F, in case of electron donating substituent it is in the order
of EDTA> 4-OCH3 > 4-CH3 > 4-N(CH3)2.Figure 2 Ferrous ion chelating assay in % of test compounds
(3a–k). Each value is expressed as mean ± SD of three replicates.
EDTA is used as a standard
Comp  R R1 Comp    R R1
  3a H H   3g H 2-F 
  3b H 4-Cl   3h H 3-F 
  3c Br H   3i H 4-F 
  3d Br 4-Cl   3j H 4-NO2
  3e 
  3f          
H 
H    
4-CH3
4-N(CH3)2
  3k H 4-OCH3
O
O
O
R
+
O
R
1
CH3COOH
NH4OAC
OO
N
O O
RR
R
1
reflux 8-10 h
1(a-b) 2(a-k) 3(a-k)
Scheme 1 Synthesis of 2, 6-bis (1-coumarin-2-yl)-4-(4-substituted phenyl) pyridine derivatives (3a–k).
Synthesis of some 2, 6-bis (1-coumarin-2-yl)-4-(4-substituted phenyl) pyridine derivatives as potent biological agents S13434. Conclusion
In conclusion, we have designed an efﬁcient synthetic route for
the synthesis of compounds 3a–k. The antimicrobial results re-
vealed that the compounds containing the halogen or electron
withdrawing substituents either on the coumarin or phenyl
ring exhibited potent antimicrobial and antioxidant activities.
In the antibacterial studies, compounds bearing a bromo
group in addition to a chloro group exhibited greater activity
than those bearing only the chloro group. This observation
suggests that di-substitution in the target compounds by halo-
gens enhanced the antimicrobial and antioxidant potential.
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